This approval represents another significant regulatory achievement for Hoyotek Biomedical in the Australian market, following its COVID-19 triple (COVID-19/Flu A/Flu B) and quadruple (COVID-19/Flu A/Flu B/RSV) combo test kits.

The seminar brought together leading experts in clinical diagnostics and high-quality partners from across the country, focusing on three core areas: respiratory infection screening, early Alzheimer's disease (AD) screening, and early cancer screening. Hoyotek presented its latest technological achievements and product pipelines.

Hoyotek Biomedical Co., Ltd. and Wantai BioPharm Co., Ltd. announced a strategic collaboration to co-develop precision diagnostic solutions for neurodegenerative disorders. The partnership will integrate Hoyotek's expertise in neurological biomarkers with Wantai's commercialization capabilities to create end-to-end solutions spanning early detection, diagnosis, and monitoring.

Hoyotek's Influenza A/B/Corona Virus (COVID-19)/RSV Antigen Rapid Test (Colloidal Gold) has received regulatory approval from the Australian Therapeutic Goods Administration (TGA).

Hoyotek'sAmyloidBeta(1-42)/PhosphorylatedTau181RapidTestKit(FluorescenceImmunochromatographicAssay)hassuccessfullyobtainedtheregistrationcertificatefromtheMalaysianMinistryofHealth(MOH).Thismarksa...

Donation 200,000 RMB Alzheimer's Disease test reagents in Nov 2023

Hoyotek participated in the PHARMEDI VIETNAM exhibition.

OurcompanyCOVID-19ProductobtainedCEcertification.Category：CompanyNewsPublishedDate：2020-12-15OnDecember8,2020, HoyotekBiomedicalCo.,Ltd.CoronaVirusDisease2019(COVID-19)ProductCoronaVirus(COVID-1...